重组凝血八因子及相关药物研究进展  

Review of recombinant coagulation factor Ⅷ and related drugs

作　　者：董艳荣 王丽 

机构地区：[1]苏州康宁杰瑞生物科技有限公司,苏州215125

出　　处：《中国新药杂志》2017年第14期1674-1682,共9页Chinese Journal of New Drugs

摘　　要：从首个重组凝血八因子产品于1992年在美国上市以来,重组产品在血友病A的治疗领域取得了显著进展,在发达国家占据主要市场份额;随着对蛋白结构、功能和作用机理的深入研究,逐步改善重组蛋白的分子结构和生产工艺,在提高产品安全性的同时,满足患者用药的方便性和依从性。本篇综述概述了重组凝血八因子相关产品的分子结构和生产工艺。Since the first recombinant clotting factorⅧ product was marketed in the United States in 1992, the recombinant products have made significant progress in the treatment of hemophilia A, and occupied a major market share in developed countries. With the in-depth study of the structures, funetions and action mechanisms of proteins, molecular structure and manufacturing process were gradually improved. The patient convenience anti compliance are being increased while product safety being improved. This review summarizes the molecular structures and produetion processes of recombinant coagulation factor Ⅷ related produets.

关 键 词：血友病A 重组凝血八因子 分子结构 生产工艺 

分 类 号：R972[医药卫生—药品]